BVF as of Dec. 31, 2016
Portfolio Holdings for BVF
BVF holds 29 positions in its portfolio as reported in the December 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 18.4 | $91M | 3.3M | 28.05 | |
| Cytokinetics (CYTK) | 11.8 | $59M | 4.9M | 12.15 | |
| Chemocentryx | 11.6 | $58M | 7.8M | 7.40 | |
| Array BioPharma | 8.8 | $44M | 5.0M | 8.79 | |
| Concert Pharmaceuticals I equity | 5.4 | $27M | 2.6M | 10.29 | |
| Xenon Pharmaceuticals (XENE) | 4.7 | $23M | 3.0M | 7.70 | |
| Forward Pharma A/s | 4.2 | $21M | 1.4M | 15.01 | |
| Cti Biopharma | 3.6 | $18M | 45M | 0.40 | |
| Colucid Pharmaceuticals | 3.5 | $18M | 484k | 36.40 | |
| Glycomimetics (GLYC) | 3.5 | $17M | 2.8M | 6.10 | |
| Oncomed Pharmaceuticals | 2.7 | $14M | 1.8M | 7.71 | |
| Cascadian Therapeutics | 2.7 | $14M | 3.1M | 4.31 | |
| Infinity Pharmaceuticals (INFIQ) | 2.1 | $11M | 7.9M | 1.35 | |
| Achillion Pharmaceuticals | 2.0 | $10M | 2.4M | 4.13 | |
| Fate Therapeutics (FATE) | 1.9 | $9.4M | 3.8M | 2.51 | |
| ArQule | 1.9 | $9.3M | 7.4M | 1.26 | |
| Esperion Therapeutics (ESPR) | 1.8 | $8.9M | 713k | 12.52 | |
| Aduro Biotech | 1.7 | $8.5M | 746k | 11.40 | |
| Immune Design | 1.5 | $7.3M | 1.3M | 5.50 | |
| Cytomx Therapeutics (CTMX) | 1.2 | $6.1M | 555k | 10.99 | |
| Gtx Inc Del | 1.2 | $5.9M | 1.1M | 5.28 | |
| Sunesis Pharmaceuticals Inc Ne | 1.0 | $5.0M | 1.4M | 3.62 | |
| Nivalis Therapeutics | 0.8 | $4.2M | 1.9M | 2.24 | |
| Orexigen Therapeutics Inc. 144a 2 3/4% Due 12/1/2020 Jd1 note 2.750%12/0 | 0.6 | $3.0M | 10M | 0.30 | |
| Pieris Pharmaceuticals (PIRS) | 0.5 | $2.6M | 1.9M | 1.41 | |
| Pain Therapeutics | 0.3 | $1.3M | 2.3M | 0.57 | |
| Orexigen Therapeutics | 0.3 | $1.3M | 735k | 1.74 | |
| Xoma Corp Del (XOMA) | 0.3 | $1.3M | 303k | 4.22 | |
| Anthera Pharmaceutcls | 0.0 | $40k | 62k | 0.64 |
